WuXi AppTec Raises $1.01 Billion in Hong Kong Share Sale
(Bloomberg) -- WuXi AppTec Co., the Shanghai-listed contract medical researcher, has raised $1.01 billion after pricing its Hong Kong first-time share sale above the midpoint of a marketed range, according to people with knowledge of the matter.
The Chinese company sold 116.5 million shares at HK$68 apiece, the people said, asking not to be identified because the information is private. The shares were offered at HK$64.10 to HK$71.50 each. The final pricing is lower than the guidance WuXi AppTec's deal arrangers gave Thursday, when they told investors that orders below HK$70 per share would likely miss out.
WuXi AppTec is completing its offering after a slump in Chinese drug stocks amid concern the government is driving down generic drug prices. CSPC Pharmaceutical Group Ltd., which is bidding to provide drugs to Chinese cities through a centralized procurement program, tumbled 14 percent Thursday in its biggest decline since 2008. Sino Biopharmaceutical Ltd. dropped almost 16 percent.Â
An external representative for WuXi AppTec said she couldn't immediately comment. IFR reported the the pricing earlier Friday, citing unidentified people.
Morgan Stanley, Huatai Securities Co. and Goldman Sachs Group Inc. are joint sponsors of Wuxi AppTec's Hong Kong listing.
To contact the reporter on this story: Crystal Tse in Hong Kong at ctse44@bloomberg.net
To contact the editors responsible for this story: Ben Scent at bscent@bloomberg.net, Timothy Sifert
©2018 Bloomberg L.P.
-
High US Salaries, No Green Card Certainty: The Financial Calculation Facing Indian H-1B Families
The suspension of PERM processing at eight technology employers does not cancel existing H-1B visas. What it does is force a question many Indian families have been avoiding: is the US salary worth tying your career and family plans to one employer?
-
Swiggy vs Eternal: Food Delivery's Two Rivals Are No Longer In The Same Race
Eternal is building a private AI assistant, dark.ai. Swiggy is still working out how to make Instamart pay, with an operating loss of Rs 895 crore in the July-September quarter while Blinkit stayed profitable.
-
Where You Live Shapes How You Get To Work | The Reason Why
Two-wheelers are the most popular way to get to work in India, accounting for nearly 43% of workplace commutes.
-
Unhedged Position: Can India See An Indonesia-Style Time Correction?
The Nifty is trading below levels it first clocked in 2024. Is there, then, as I have suggested in the headline, potential that the current time correction drags on painfully for the next three-five, even ten years?
-
Navigating Friction And Energy Realities: An Analysis Of Marco Rubio's October Visit To India
Occurring at a critical juncture marked by stalled trade negotiations and escalating geopolitical pressures over global energy supplies, the visit offers a profound window into modern US-India relations.
-
India Exports Capital. Why Not Export Trusteeship?
The big question, then, is whether India can build an institution that global borrowers, investors, banks, and lawyers can trust, even without an Indian connection.
-
France's Economy & Politics Are In Crisis | The Reason Why
Let's look at how the French economy and politics evolved under Nicolas Sarkozy, Franois Hollande and Emmanuel Macron.
-
You May Inherit The Business. You Must Earn Its Credibility.
Succession tests the founder's ability to share authority as much as it tests the next generation's readiness to assume it.
-
Signing Deals Is One Thing; Making Them Work Is Another | The Week In Whys
Sometimes, things don't turn out as planned. Indian companies have lost some bids to rivals, some projects won't produce until 2030.
-
FOMC Wall, PERM Suspension, Hospital Stocks | Talking Points This Week
A PERM suspension would directly affect green-card sponsorship rather than H-1B visas, so the near-term earnings impact could remain relatively limited. The key question is whether this marks a new phase in US scrutiny of Indian IT.
